European Biotech Is Specialty Pharma

Europe's investment environment has forced much of the biotech sector to morph into specialty pharma. The situation isn't likely to change fast. Executives had best adapt, rather than complain.

By Melanie Senior

Investors' calls for late-stage, lower-risk products and the promise of near-term revenues aren't new, either in European or US biotech....

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Global Vision

More from In Vivo